Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled time : 12:20 save search
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
Published: 2023-10-28 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
fy2024 pharma results
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
Published: 2023-05-06 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
week disease abbvie
AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting
Published: 2023-03-13 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.47%
H: 2.9%
C: 1.98%
abbvie meeting
Retinal drugs market size to increase by USD 7.27579 billion; North America to account for 42% of market growth - Technavio
Published: 2023-02-08 (Crawled : 12:20) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.72%
H: 0.52%
C: -0.08%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: 0.28%
H: 0.21%
C: -0.41%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.19%
H: 0.65%
C: -0.55%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
MGTX | News | $5.02 -4.38% -4.58% 240K
|
Health Technology
|
| O: -1.14%
H: 4.62%
C: -0.77%
america growth market
Biologics CDMO Secondary Packaging Global Market Report 2022: Sector to Generate $3.62 Billion by 2030
Published: 2023-01-28 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
| Email alert
Add to watchlist
global report market
AbbVie Braves Humira LOE, Remains Confident in Long-Term Growth
Published: 2023-01-11 (Crawled : 12:20) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.26%
H: 0.08%
C: -1.29%
abbvie humira growth
AbCellera and AbbVie Partner to Advance New Antibody Therapies
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
ABCL | $3.92 0.0% 770K
|
|
| O: 9.97%
H: 1.44%
C: -6.64%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
antibody
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.36%
H: 0.99%
C: 0.29%
IRWD | $7.59 -0.78% -0.79% 3.6M
|
Health Technology
|
| O: 2.92%
H: 1.42%
C: 0.71%
pharmaceuticals year financial
The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery
Published: 2022-09-22 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.07%
H: 3.03%
C: 2.0%
beauty report
AbbVie to Host Second-Quarter 2022 Earnings Conference Call
Published: 2022-07-08 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
conference
AbbVie's Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn's Disease
Published: 2022-06-20 (Crawled : 12:20) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
il-23 skyrizi disease fda
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
il-23 skyrizi fda disease active approval
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Published: 2022-06-03 (Crawled : 12:20) - globenewswire.com
CELU | News F | $3.17 -4.23% -4.42% 42K
|
|
| O: 1.52%
H: 7.43%
C: 4.53%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.54%
H: 0.99%
C: 0.29%
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: -3.4%
H: 7.67%
C: -1.65%
KURA | $17.66 -1.83% -1.87% 1.7M
|
Health Technology
|
| O: 1.09%
H: 2.08%
C: 0.97%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 1.01%
H: 2.9%
C: -4.64%
CALT | News | $18.3 -2.35% -2.4% 6.1K
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: -1.3%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -1.43%
H: 0.0%
C: 0.0%
AbbVie to Host First-Quarter 2022 Earnings Conference Call
Published: 2022-04-14 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
conference
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
Published: 2021-06-12 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
leukemia phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.